Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $23.00.

A number of analysts recently issued reports on the company. Barclays reissued an “overweight” rating and issued a $28.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright lifted their target price on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday. Mizuho set a $20.00 price target on shares of Corvus Pharmaceuticals in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Thursday, December 11th.

Corvus Pharmaceuticals Price Performance

NASDAQ CRVS opened at $21.41 on Wednesday. The firm’s fifty day moving average price is $8.25 and its 200 day moving average price is $6.74. Corvus Pharmaceuticals has a 12 month low of $2.54 and a 12 month high of $22.10. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -40.40 and a beta of 0.70.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, sell-side analysts forecast that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Key Headlines Impacting Corvus Pharmaceuticals

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Corvus reported positive cohort 4 Phase 1 results for soquelitinib in atopic dermatitis, with efficacy in treatment‑resistant patients and a favorable safety profile; the release triggered the rally and the company said results confirm progression to mid‑stage testing. Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
• Positive Sentiment: Analyst/market reaction: Mizuho raised its price target to $20 and at least one firm offered a Buy; media coverage framed soquelitinib as having “best‑in‑class” potential in dermatology, supporting upside expectations. Mizuho raises Corvus Pharmaceuticals stock price target to $20 on strong trial data, Top January Pick
• Neutral Sentiment: Full transcript / management commentary on the Phase 1 cohort 4 readout is available (useful for parsing durability, responder rates and safety nuance); this gives investors more detail to assess how differentiated soquelitinib may be. Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
• Neutral Sentiment: Corvus suspended its at‑the‑market (ATM) equity program — typically a procedural move tied to a planned block offering or to manage issuance while an underwritten deal is in progress; watch filings for timing and size. Corvus Pharmaceuticals Suspends At-The-Market Equity Program
• Negative Sentiment: Corvus launched a $150M underwritten public offering of common stock and pre‑funded warrants (plus a 30‑day option on additional shares). While proceeds fund R&D and trials, the offering creates dilution risk and is likely the near‑term offset to the trial‑driven rally. Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Institutional Trading of Corvus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $672,000. Towerview LLC grew its position in Corvus Pharmaceuticals by 33.3% in the 2nd quarter. Towerview LLC now owns 170,000 shares of the company’s stock valued at $680,000 after buying an additional 42,500 shares during the last quarter. ProShare Advisors LLC acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at $54,000. Geode Capital Management LLC increased its stake in Corvus Pharmaceuticals by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock valued at $5,448,000 after buying an additional 771,454 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Corvus Pharmaceuticals during the 2nd quarter worth $49,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.